The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts.

BACKGROUND: Emerging evidence suggests that gap junction-mediated intercellular transmission of ions, metabolites and/or second messengers may serve as important determinants of myocyte viability. Our aim was to determine, using isolated buffer-perfused mouse hearts, whether the cardioprotection achieved with ischemic preconditioning (PC) is due in part to: (i) disruption of cell-cell coupling (manifest as a loss in the primary gap junction protein, connexin 43 [Cx43]) and resultant impaired transmission of a 'death' messenger, or conversely, (ii) transfer of a humoral 'survival' factor via existing gap junctions.
METHODS: To explore the first possibility, we employed immunostaining to visualize and quantify Cx43 in hearts subjected to 212 min of PC ischemia or a matched control period. To test the converse corollary, we assessed the effect of heptanol-an agent well recognized to rapidly and reversibly uncouple gap junctions--on the reduction of infarct size (delineated by tetrazolium staining) achieved with PC.
RESULTS: We found no evidence of a deficit in Cx43 immunoreactive signal in response to the PC stimulus. Area of necrosis (AN) was, as expected, reduced in hearts that received PC ischemia vs. controls (31+/-3% vs. 40+/-3% of the left ventricle [LV]; P<.01). However, treatment with heptanol rendered PC ineffective in eliciting protection (AN/LV: 42+/-1%).
CONCLUSIONS: Our results suggest that gap junction-mediated transfer of an as-yet unknown 'survival' factor-rather than disrupted transfer of a 'death messenger'-may play a role in the increased resistance to infarction conferred by antecedent PC ischemia in mouse heart.